benzgalantamine gluconate · Alpha Cognition · NDA 218549
Zunveyl
Earliest generic entry, as listed · earliest of 3 marketed strengths
23 Jul 2045
Blocked by patent: US 12551491. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12551491 | use U-713 | 23 Jul 2045 |
| US 12208167 | product, use U-713 | 26 Feb 2044 |
| US 11795176 | substance, use U-713 | 13 Jan 2042 |
| US 9763953 | use U-713 | 1 Dec 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 218549 · 001 · RLD | tablet, delayed release, oral | EQ 5MG BASE | 23 Jul 2045 |
| 218549 · 002 · RLD | tablet, delayed release, oral | EQ 10MG BASE | 23 Jul 2045 |
| 218549 · 003 · RLD | tablet, delayed release, oral | EQ 15MG BASE | 23 Jul 2045 |